[HTML][HTML] Synergy of combining methionine restriction and chemotherapy: the disruptive next generation of cancer treatment

Y Kubota, Q Han, Y Aoki, N Masaki… - Cancer Diagnosis & …, 2023 - ncbi.nlm.nih.gov
All cancer cell types are methionine-addicted, which is termed the Hoffman effect. Cancer
cells, unlike normal cells, cannot survive without large amount of methionine. In general …

[HTML][HTML] Targeting methionine addiction of cancer cells with methioninase

VS Pokrovsky, L Abo Qoura, EA Demidova, Q Han… - Biochemistry …, 2023 - Springer
All types of cancer cells are addicted to methionine, which is known as the Hoffman effect.
Restricting methionine inhibits the growth and proliferation of all tested types of cancer cells …

Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet

Y Kubota, Q Han, K Hamada, Y Aoki… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Rectal cancer is a recalcitrant disease with limited treatment options. Pre-
clinical studies have shown the efficacy of methionine restriction with a low-methionine diet …

Elimination of axillary-lymph-node metastases in a patient with invasive lobular breast cancer treated by first-line neo-adjuvant chemotherapy combined with …

Y Kubota, Q Han, N Masaki, C Hozumi… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Invasive lobular carcinoma (ILC) of the breast has a low complete-
response rate in the neoadjuvant-chemotherapy setting. The addiction to methionine is a …

Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer

M Miyake, K Miyake, Q Han, K Igarashi… - Biochemical and …, 2023 - Elsevier
Gastric cancer is highly malignant and recalcitrant to first line chemotherapies that include 5-
fluorouracil (5-FU). Cancer cells are addicted to methionine for their proliferation and …

Oral-recombinant methioninase in combination with rapamycin eradicates osteosarcoma of the breast in a patient-derived orthotopic xenograft mouse model

N Masaki, Q Han, C Samonte, NF Wu… - Anticancer …, 2022 - ar.iiarjournals.org
Abstract Background/Aim: Primary osteosarcoma of the breast is a very rare malignancy that
shares histological features with osteosarcoma. It is also highly sensitive to methionine …

[HTML][HTML] Dietary manipulation of amino acids for cancer therapy

JJ Jiménez-Alonso, M López-Lázaro - Nutrients, 2023 - mdpi.com
Cancer cells cannot proliferate and survive unless they obtain sufficient levels of the 20
proteinogenic amino acids (AAs). Unlike normal cells, cancer cells have genetic and …

Oral installation of recombinant methioninase-producing Escherichia coli into the microbiome inhibits colon-cancer growth in a syngeneic mouse model

Y Kubota, Q Han, K Hamada, Y Aoki… - Cancer Genomics & …, 2022 - cgp.iiarjournals.org
Background/Aim: All cancer types so far tested are methionine-addicted. Targeting the
methionine addiction of cancer with recombinant methioninase (rMETase) has shown great …

Oral-recombinant methioninase lowers the effective dose and eliminates toxicity of cisplatinum for primary osteosarcoma of the mammary gland in a patient-derived …

N Masaki, Q Han, NF Wu, C Samonte, J Wu, C Hozumi… - in vivo, 2022 - iv.iiarjournals.org
Abstract Background/Aim: Primary osteosarcoma of the mammary gland is a very rare
disease, accounting for under 1% of all mammary gland malignancies. There is no …

Recombinant oral methioninase (o-rMETase) combined with oxaliplatinum plus 5-fluorouracil improves survival of mice with massive colon-cancer peritoneal …

MJ Kim, Q Han, M Bouvet, RM Hoffman… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: The present study aimed to determine if oral methioninase (o-rMETase)
combined with oxaliplatinum (OXA) plus 5-fluorouracil (5-FU) increases survival of mice with …